Drug Profile

DZ 4001

Alternative Names: DZ-4001

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Dizal Pharmaceutical
Developer AstraZeneca; Dizal Pharmaceutical
Class Small molecules
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Kidney disorders

Most Recent Events

28 May 2023 No recent reports of development identified for preclinical development in Kidney-disorders in China
26 Apr 2019 Pharmacodynamics data from preclinical trials in kidney disorders released by Dizal Pharmaceutical before April 2019 (Company pipeline, April 2019)
25 Apr 2019 Dizal Pharmaceutical plans the clinical trials for Kidney disease in World in 2019 or 2020 (Dizal Pharmaceutical pipeline, April 2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com